GeneSight vs Genomind for Treatment-Resistant Depression: What Residential Mental Health Programs Actually Use

When first- and second-line antidepressants fail — a scenario that defines treatment-resistant depression (TRD) — residential mental health programs increasingly turn to pharmacogenomic (PGx) testing to shortcut the trial-and-error cycle. Two panels dominate the U.S. market: GeneSight (Myriad Genetics) and Genomind (Genomind Professional PGx Express). Both analyze the same core cytochrome P450 (CYP450) enzymes that metabolize psychiatric medications, but they differ in gene coverage, reporting format, insurance behavior, and clinical workflow. At Bodhi Mental Health, our medical team uses PGx testing selectively — not universally — and the choice between GeneSight and Genomind is driven by the patient’s medication history, comorbidities, and how quickly we need actionable data.

Call 877-883-0780 to speak with our admissions clinicians about whether PGx testing fits your treatment plan.

What Pharmacogenomic Testing Actually Measures

PGx panels do not diagnose depression, predict response, or tell a psychiatrist which drug will work. What they do is tell us how a patient metabolizes candidate medications based on inherited variants in specific enzymes and receptors — data that either de-risks a prescribing decision or flags one to avoid entirely.

Core CYP450 Enzymes

The four CYP450 enzymes most relevant to psychiatric prescribing are:

• CYP2D6 — metabolizes most SSRIs (paroxetine, fluoxetine), SNRIs (venlafaxine, duloxetine), tricyclics, and atypical antipsychotics (risperidone, aripiprazole)
• CYP2C19 — metabolizes citalopram, escitalopram, sertraline, and clomipramine
• CYP3A4 — broad metabolizer for benzodiazepines, buspirone, and quetiapine
• CYP1A2 — clozapine, olanzapine, and a share of duloxetine

Patients are classified as poor, intermediate, normal (extensive), rapid, or ultra-rapid metabolizers for each enzyme. A CYP2D6 poor metabolizer given standard-dose venlafaxine, for example, may accumulate toxic levels; an ultra-rapid CYP2C19 metabolizer on escitalopram may never reach therapeutic serum concentration regardless of dose escalation.

Pharmacodynamic Genes

Beyond metabolism, both panels report on genes affecting drug response — most commonly SLC6A4 (serotonin transporter), HTR2A (serotonin receptor), COMT (catecholamine breakdown), and MTHFR (folate metabolism, relevant when considering l-methylfolate augmentation for partial SSRI responders).

GeneSight: The Prescribing Guide Approach

GeneSight (Myriad Genetics) tests 15 genes and produces a color-coded report: green (use as directed), yellow (moderate gene-drug interaction), red (significant interaction, consider alternative). Its combinatorial algorithm bundles CYP450 and pharmacodynamic data into a single sortable list of psychiatric medications.

Strengths for Residential Programs

• The green/yellow/red format is fast to interpret during 15-minute medication management sessions
• Medicare and many commercial insurers cover GeneSight for patients with TRD or a documented failed trial
• Turnaround is typically 3–5 business days from lab receipt
• Combinatorial reporting captures interactions between metabolism and target-receptor genotype

Limitations

• The proprietary algorithm is not fully transparent; some psychiatrists prefer raw genotype data
• Coverage of newer agents (esketamine, brexanolone) is limited
• Lithium is not included — you still need clinical monitoring and serum levels

We already published a detailed explainer on how GeneSight guides medication decisions in residential care. What follows is the comparison patients and referring providers ask for most often.

Genomind: The Deep-Data Approach

Genomind Professional PGx Express tests 24 genes — more than GeneSight — and produces a longer clinician report with dose-adjustment guidance grounded in Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. Rather than a stoplight visual, Genomind provides written clinical narratives for each medication category.

Strengths for Residential Programs

• Broader gene panel, including ADRA2A (attention/ADHD medications), CACNA1C (mood stabilizers), and OPRM1 (opioid response, relevant when treating comorbid chronic pain)
• CPIC-aligned dose recommendations, giving prescribers defensible clinical rationale
• Strong reporting on ADHD stimulants and mood stabilizers, useful for bipolar-spectrum and dual-mood patients
• Genomind’s Mindful Choices tool integrates PGx results with medication history and current symptoms

Limitations

• Reports are dense; new prescribers need onboarding to read them efficiently
• Insurance coverage is less consistent than GeneSight, especially outside a clear TRD diagnosis
• Turnaround is 5–7 business days, meaningful when residential stays are compressed

Which One Do Residential Programs Actually Use?

The honest answer: it depends on the patient. At Bodhi Mental Health, our psychiatric team defaults to GeneSight when the clinical question is narrow (“this patient has failed two SSRIs — what’s next?”) and switches to Genomind when the case is complex — a patient with bipolar II, comorbid ADHD, and chronic pain, for example, where the broader gene panel produces more actionable data.

Decision Factors We Weigh

• Insurance authorization — GeneSight clears prior authorization faster in most commercial plans
• Diagnostic complexity — Genomind’s broader panel earns its cost in polypharmacy cases
• Prescriber familiarity — some psychiatrists have used one panel for years and read it faster
• Turnaround pressure — for a compressed residential admission, we need actionable data within the first week

Timing: Pre-Admission vs. During Residential Stay

Timing is the single biggest clinical variable, and it’s where PGx testing either accelerates or delays a treatment plan.

Pre-Admission Testing (Ideal)

When a referring outpatient psychiatrist orders PGx testing 2–3 weeks before admission, results are typically in hand by day one of residential care. This lets our medical director begin any indicated medication adjustments during the initial evaluation rather than waiting a week into stay — critical for a 30-day residential mental health stay where every day of stabilization counts.

Testing During Admission (Common)

Most patients arrive without prior PGx results. We collect a buccal swab during the medical intake, ship overnight to the lab, and typically have GeneSight results back within 5 business days. During those 5 days, the treatment team uses clinical judgment, medication history, and family response patterns to make interim adjustments — PGx data then refines the plan going into week two.

When Testing Is Not Indicated

PGx testing is not appropriate for every admission. Patients who are stable on a current regimen, who have already been PGx-tested within the last 5 years (genotype does not change), or whose primary presentation is severe anxiety without treatment resistance often do not need repeat testing.

Integrating PGx With the Rest of Residential Care

PGx testing is one input into a treatment plan — not the plan itself. At Bodhi Mental Health, results are integrated with:

• Structured psychotherapy including DBT and other evidence-based modalities
• Serum drug-level monitoring for narrow-therapeutic-index medications (lithium, clozapine, valproate)
• Sleep, nutrition, and exercise interventions that measurably affect drug metabolism and receptor sensitivity
• Family history review for atypical medication responses that genotyping alone cannot explain

The goal is a discharge medication list that will hold up in the real world — not a laboratory-perfect regimen that falls apart at day 45 post-discharge.

What This Means for Families and Referring Providers

If you or a loved one is facing another antidepressant trial after multiple failures, PGx testing is worth asking about — but be specific about the question you want answered. “Which SSRI has the best chance?” is a GeneSight-style question. “How do we optimize a complex regimen across mood, ADHD, and pain?” is a Genomind-style question. And in both cases, the test is a starting point, not a shortcut around the clinical work of a full residential admission.

To discuss whether pharmacogenomic testing fits into your admission plan at Bodhi Mental Health, call our admissions team at 877-883-0780. We’ll review your medication history, coordinate insurance authorization if PGx is indicated, and — when possible — get testing underway before you arrive so results are actionable from day one.

A Note on Cost and Insurance

Out-of-pocket cost is often the deciding factor when insurance denies coverage. GeneSight’s list price runs approximately $2,000, though Myriad’s patient assistance program caps most out-of-pocket obligations at $330 or less for commercially insured patients, and Medicare beneficiaries often pay nothing when the diagnostic criteria are met. Genomind’s list price is comparable, with a similar patient assistance structure but somewhat less consistent commercial coverage. Our admissions team handles prior authorization for both panels before testing is ordered, so patients are never surprised by a bill mid-stay. When neither panel is covered, we can help you decide whether self-pay PGx is worth the investment given your specific medication history — sometimes it clearly is, and sometimes clinical management alone is the smarter path.